替米沙坦联合骨化三醇在糖尿病肾病治疗中的应用

Application of telmisartan combined with calcitriol in the treatment of diabetic nephropathy

目的分析替米沙坦联合骨化三醇治疗糖尿病肾病的临床疗效。方法56例糖尿病肾病患者,按照奇偶数原则分为对照组和观察组,每组28例。对照组给予替米沙坦片治疗,观察组给予替米沙坦片+骨化三醇胶丸治疗。比较两组患者治疗前后的血钾、血钙、血磷、24 h尿蛋白定量、尿微量白蛋白水平。结果两组患者治疗前后的血钾、血钙、血磷水平比较,差异均无统计学意义(P>0.05)。治疗后,观察组患者24 h尿蛋白定量(1.53±0.40)g、尿微量白蛋白(73.47±8.69)mg/dl均低于对照组的(1.92±0.54)g、(110.40±9.20)mg/dl,差异均具有统计学意义(P<0.05)。结论针对糖尿病肾病患者,临床选择替米沙坦与骨化三醇联合治疗的效果是非常显著的,有助于改善机体24 h尿蛋白定量与尿微量白蛋白含量,促进病情好转。

Objective To analyze the clinical efficacy of telmisartan combined with calcitriol in the treatment of diabetic nephropathy.Methods A total of 56 patients with diabetic nephropathy were divided into control group and observation group according to even-odd number method,with 28 cases in each group.The control group was treated with telmisartan,and the observation group was treated with telmisartan combined with calcitriol soft capsules.The blood potassium,blood calcium,blood phosphorus,24-h urine protein quantification,and urine microalbumin levels before and after treatment were compared between the two groups.Results There was no statistically significant difference in blood potassium,blood calcium and blood phosphorus before and after treatment between the two groups(P>0.05).After treatment,the 24-h urine protein quantification and urine microalbumin of the observation group were(1.53±0.40)g and(73.47±8.69)mg/dl,which were all lower than(1.92±0.54)g and(110.40±9.20)mg/dl of the control group,and the difference was statistically significant(P<0.05).Conclusion For patients with diabetic nephropathy,the clinical effect of telmisartan combined with calcitriol is very significant,which is helpful to improve the content of 24-hurinary protein quantification and microalbumin and promote the improvement of the disease.